In certain clinical contexts, adjunctive therapies may be considered under established regulatory pathways, such as the TGA’s Special Access Scheme (SAS-B) or via an Authorised Prescriber.

These pathways are used to access treatments not currently registered on the Australian Register of Therapeutic Goods (ARTG) but which may have specific clinical merit in defined scenarios.

When Special Access TGA Prescribing of Adjunctive Treatments Be Considered?

Following thorough medical assessment, individualised treatment may be considered for patients with:

• Chronic or treatment-resistant soft tissue injuries

• Recovery following musculoskeletal surgery

• Certain inflammatory or repair-limiting conditions

Note: These treatments are not provided for cosmetic, wellness, aesthetic enhancement, or general anti-ageing purposes. They are not substitutes for first-line medical, surgical, or rehabilitative interventions.

Our Clinical Process

We follow a structured and ethically guided approach to determine whether adjunctive treatment is appropriate:

1. Initial Clinical Assessment

All patients begin with a telehealth consultation with a qualified doctor. This includes:

• Medical history review

• Assessment of previous treatments and imaging

• Consideration of standard care options and alternatives

2. Pathology and Diagnostic Screening

Relevant tests may include:

• Hormonal or inflammatory markers

• Imaging studies

• Functional assessments as clinically indicated

3. Eligibility Review and Regulatory Application

If clinically appropriate, your doctor may submit:

• A Special Access Scheme (SAS-B) application on your behalf, or

• Initiate prescribing under an existing Authorised Prescriber framework

4. Informed Consent and Monitoring

If prescribing proceeds:

• You will receive a detailed explanation of the treatment rationale, risks, benefits, and alternatives

• Follow-up appointments and safety monitoring will be arranged

Our Regulatory Commitment

Our clinic adheres to:

• Therapeutic Goods Administration (TGA) regulations

• AHPRA’s Advertising Guidelines and Schedule 4 advertising restrictions

• The Medical Board of Australia’s Code of Good Medical Practice

We do not advertise or promote specific treatment names. No claims of benefit or outcomes are made. All decisions are made on a case-by-case basis in line with legal, ethical, and clinical requirements.

Important Patient Notes:

• Not all patients will be eligible for adjunctive treatment options.

• Most cases are better served through conventional therapies

• A full consultation is mandatory before any prescribing

• No prescriptions are issued based solely on questionnaires or forms

Interested in a Clinical Review?

If you’re managing a chronic or treatment-resistant condition and would like a comprehensive review:

• Book a consultation

• Complete our intake assessment

• Undergo relevant pathology
  If clinically suitable, your doctor will develop a personalised plan within the appropriate prescribing framework.